HCA Healthcare, Inc. (NYSE:HCA) Shares Acquired by Robbins Farley

Robbins Farley raised its holdings in HCA Healthcare, Inc. (NYSE:HCA) by 5.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,940 shares of the company’s stock after buying an additional 234 shares during the quarter. Robbins Farley’s holdings in HCA Healthcare were worth $1,483,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of HCA. MML Investors Services LLC boosted its holdings in shares of HCA Healthcare by 31.7% in the 3rd quarter. MML Investors Services LLC now owns 17,816 shares of the company’s stock valued at $7,241,000 after purchasing an additional 4,285 shares during the last quarter. Meritage Group LP acquired a new stake in HCA Healthcare during the third quarter worth about $150,548,000. Galvin Gaustad & Stein LLC acquired a new position in shares of HCA Healthcare in the 4th quarter valued at about $18,044,000. Alpha DNA Investment Management LLC acquired a new stake in HCA Healthcare during the 3rd quarter worth approximately $869,000. Finally, NRI Wealth Management LC purchased a new stake in HCA Healthcare during the fourth quarter worth approximately $2,896,000. 62.73% of the stock is currently owned by hedge funds and other institutional investors.

HCA Healthcare Price Performance

Shares of NYSE HCA opened at $334.65 on Tuesday. HCA Healthcare, Inc. has a twelve month low of $289.98 and a twelve month high of $417.14. The company has a market capitalization of $84.77 billion, a price-to-earnings ratio of 15.23, a price-to-earnings-growth ratio of 1.13 and a beta of 1.64. The company has a current ratio of 1.08, a quick ratio of 0.97 and a debt-to-equity ratio of 69.07. The business has a 50 day simple moving average of $313.33 and a 200-day simple moving average of $353.50.

HCA Healthcare (NYSE:HCA) last posted its earnings results on Friday, January 24th. The company reported $6.22 EPS for the quarter, beating the consensus estimate of $6.03 by $0.19. HCA Healthcare had a return on equity of 586.47% and a net margin of 8.16%. During the same period in the previous year, the company posted $5.90 EPS. As a group, equities research analysts expect that HCA Healthcare, Inc. will post 24.89 earnings per share for the current year.

HCA Healthcare Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 17th will be given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 0.86%. This is a boost from HCA Healthcare’s previous quarterly dividend of $0.66. The ex-dividend date is Monday, March 17th. HCA Healthcare’s payout ratio is presently 12.02%.

Insider Buying and Selling

In other HCA Healthcare news, insider Erol R. Akdamar sold 2,900 shares of the stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $353.00, for a total transaction of $1,023,700.00. Following the transaction, the insider now owns 6,843 shares in the company, valued at $2,415,579. This trade represents a 29.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Phillip G. Billington sold 3,897 shares of the company’s stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $350.00, for a total transaction of $1,363,950.00. Following the sale, the senior vice president now directly owns 52,702 shares of the company’s stock, valued at approximately $18,445,700. This represents a 6.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.70% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

HCA has been the subject of a number of research reports. Truist Financial decreased their price target on shares of HCA Healthcare from $430.00 to $390.00 and set a “buy” rating for the company in a research report on Monday, January 6th. Bank of America lowered their target price on HCA Healthcare from $380.00 to $370.00 and set a “buy” rating for the company in a research note on Monday, January 27th. Morgan Stanley decreased their price target on HCA Healthcare from $406.00 to $355.00 and set an “equal weight” rating for the company in a report on Tuesday, December 17th. TD Cowen decreased their target price on shares of HCA Healthcare from $450.00 to $440.00 and set a “buy” rating for the company in a research note on Monday, October 28th. Finally, Barclays cut their price objective on shares of HCA Healthcare from $392.00 to $366.00 and set an “overweight” rating on the stock in a report on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $385.67.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.